Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth 2005;9:41 52. 10. Machin D, Devine P. The effect of temperature and apro- tinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol 2005;37:265 71. 11. Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S. An investigation of a new activated clotting time MAX-ACT in patients undergoing extracorporeal circula- tion. Anesth Analg 2001;92:578 83. 12. Koster A, Fischer T, Praus M, et al. Hemostatic activation and in ammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002;97:837 41. 13. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time moni- toring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46 54. 14. Despotis GJ, Joist JH, Hogue CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902 8. 15. Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clot- ting time and whole blood heparin concentration. Perfusion 2006;21:285 90. 16. Hofmann B, Bushnaq H, Kraus FB, et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid anti- brinolytic therapy. Perfusion 2013;28:412 8. 17. Newsome J, Stipanovich K, Flaherty S. Comparison of heparin administration using the Rapidpoint Coag and Hepcon HMS. J Extra Corpor Technol 2004;36:139 44. 18. 